Beyfortus is the first long-acting monoclonal antibody approved by the FDA to prevent RSV-related lower respiratory tract disease in newborns and infants as well as children up to 24 months old, according to a Sept. 16 news release from the drug manufacturer.
Sanofi has started shipping doses to private healthcare providers and the CDC’s Vaccines for Children program, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
